ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Sucralfate: Drug information

Sucralfate: Drug information
(For additional information see "Sucralfate: Patient drug information" and see "Sucralfate: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Carafate
Brand Names: Canada
  • APO-Sucralfate;
  • Cytogard;
  • Sulcrate;
  • Sulcrate Plus;
  • TEVA-Sucralfate
Pharmacologic Category
  • Gastrointestinal Agent, Miscellaneous
Dosing: Adult
Duodenal ulcer

Duodenal ulcer: Oral:

Active duodenal ulcer: Suspension, tablet: Initial: 1 g four times daily for 4 to 8 weeks.

Maintenance therapy: Tablet: 1 g twice daily.

Gastroesophageal reflux disease in pregnancy

Gastroesophageal reflux disease in pregnancy (alternative agent) (off-label use):

Note: For persistent symptoms despite nonpharmacologic measures (Ref).

Oral: 1 g three times daily; if symptoms do not improve, additional or alternative therapy should be considered (Ref).

Marginal (anastomotic) ulceration after bariatric surgery

Marginal (anastomotic) ulceration after bariatric surgery (adjunctive agent) (off-label use): Oral: Suspension: 1 g four times daily in combination with twice-daily proton pump inhibitor; institutional guidelines vary; refer to center-specific protocol (Ref).

Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease

Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease (alternative agent) (adjunctive agent) (off-label use):

Note: Consider for use in patients with persistent symptoms despite other therapies; may be used in combination with other topical therapies (eg, steroid, antibiotic, anesthetic) (Ref).

Oral: Suspension: 1 g for 1 to 2 minutes after routine mouth care 4 times daily; alternatively, suspension may be applied directly to the oral ulcer 4 times daily using a cotton-tip applicator (Ref).

Proctitis due to radiation

Proctitis due to radiation (off-label use):

Note: For mild persistent rectal pain, tenesmus, or bleeding. Regimen details (eg, volume administered, duration of enema retention) may vary based on institutional protocols (Ref). An example regimen is provided:

Rectal: Retention enema: 2 g (tablets or suspension) dissolved in 20 mL water twice daily for at least 4 weeks or until resolution of symptoms; retain each enema for as long as possible or at least 5 minutes (Ref).

Upper GI toxicity following radiation therapy

Upper GI toxicity following radiation therapy (adjunctive agent) (off-label use): Oral: Suspension: 1 g four times daily generally for 2 weeks postprocedure as a component of a combination regimen (eg, with antisecretory agent[s], analgesic[s], and/or local anesthetic as needed). Optimal regimen has not been established; refer to published and institutional protocols (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Oral, rectal:

Altered kidney function:

CrCl ≥30 mL/minute: No dosage adjustment necessary (minimal systemic absorption) (Ref).

CrCl <30 mL/minute: No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (minimal systemic absorption): No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (minimal systemic absorption): No dosage adjustment necessary (Ref). However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (Ref).

CRRT: No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary. However, regular and prolonged use can lead to aluminum accumulation in patients with advanced kidney impairment; use with caution and consider alternative agent (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing. Use with caution; initiate at low end of dosage range.

Dosing: Pediatric

(For additional information see "Sucralfate: Pediatric drug information")

Peptic ulcer disease, adjunct therapy

Peptic ulcer disease, adjunct therapy: Limited data available: Infants, Children, and Adolescents: Oral: 40 to 80 mg/kg/day divided every 6 hours. Maximum dose: 1,000 mg/dose (Ref).

Esophagitis

Esophagitis: Limited data available (Ref):

Infants ≥3 months and Children <6 years: Oral: 500 mg/dose four times daily

Children ≥6 years: Oral: 1,000 mg/dose four times daily

Note: Dosing from a prospective trial of 75 patients (age range: 3 months to 13 years) who received sucralfate tablets (n=25), sucralfate suspension (n=25), or cimetidine (n=25) for reflux esophagitis. At the end of 8 weeks, 68% of patients receiving sucralfate tablet, 92% of patients receiving sucralfate suspension, and 79% of patients receiving cimetidine were asymptomatic. Sucralfate was well tolerated.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Aluminum salt is minimally absorbed (<5%); however, may accumulate in renal failure; use with caution in patients with chronic renal failure.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%: Gastrointestinal: Constipation (2%)

<1%, postmarketing, and/or case reports: Anaphylaxis, back pain, bezoar formation, bronchospasm, diarrhea, dizziness, drowsiness, dyspepsia, facial edema, flatulence, gastric distress, headache, hyperglycemia, hypersensitivity reaction, insomnia, laryngeal edema, mouth edema, nausea, pharyngeal edema, pruritus, pulmonary edema, skin rash, vertigo, vomiting, xerostomia

Contraindications

Hypersensitivity to sucralfate or any component of the formulation

Warnings/Precautions

Disease-related concerns:

• Diabetes: Hyperglycemia has been reported with sucralfate suspension in patients with diabetes; monitor glycemia closely; adjustment of antidiabetic treatment may be necessary.

• Duodenal ulceration: Because sucralfate acts locally at the ulcer, successful therapy with sucralfate should not be expected to alter the posthealing frequency of recurrence or the severity of duodenal ulceration.

• Renal impairment: Use with caution in patients with advanced kidney impairment. Sucralfate is an aluminum complex; small amounts of aluminum are absorbed following oral administration. Excretion of aluminum may be decreased in patients with advanced kidney impairment or on dialysis, increasing the risk of aluminum accumulation and toxicity (eg, aluminum osteodystrophy, osteomalacia, and encephalopathy).

Dosage form specific issues:

• Tablets: Use with caution in patients with conditions that may impair swallowing (eg, recent or prolonged intubation, tracheostomy, dysphagia, history of aspiration) or other conditions that may alter gag/cough reflexes, or diminish oropharyngeal coordination or motility; aspiration with accompanying respiratory complications has been reported.

Other warnings/precautions:

• Administration: Administer sucralfate by oral or rectal route only; fatal complications, including cerebral and pulmonary emboli, have been reported with inadvertent IV administration of sucralfate.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension, Oral:

Carafate: 1 g/10 mL (420 mL) [contains fd&c red #40 (allura red ac dye), methylparaben, sorbitol; cherry flavor]

Generic: 1 g/10 mL (10 mL, 414 mL, 420 mL)

Tablet, Oral:

Carafate: 1 g [scored; contains fd&c blue #1 (brill blue) aluminum lake]

Generic: 1 g

Generic Equivalent Available: US

Yes

Pricing: US

Suspension (Carafate Oral)

1 g/10 mL (per mL): $0.76

Suspension (Sucralfate Oral)

1 g/10 mL (per mL): $0.86 - $1.23

Tablets (Carafate Oral)

1 g (per each): $5.95

Tablets (Sucralfate Oral)

1 g (per each): $0.38 - $4.80

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension, Oral:

Sulcrate Plus: 200 mg/mL (500 mL) [contains methylparaben sodium, propylparaben sodium]

Tablet, Oral:

Cytogard: 1 g

Sulcrate: 1 g

Generic: 1 g

Administration: Adult

Oral: Administer on an empty stomach. Shake suspension well before use. Do not administer antacids within 30 minutes of administration of sucralfate. In general, separate administration of other oral medications and sucralfate by at least 2 hours; consult drug interactions database for additional information.

Rectal: Enema: Prepare for immediate use. Dissolve 2 sucralfate 1 g tablets in 20 mL of warm water, or 10 mL sucralfate suspension (1 g per 5 mL) in 10 to 20 mL of warm, not hot, water. Fill delivery apparatus (ie, enema bag, Toomey syringe, or 60 mL catheter tip syringe with 14F self-retaining foley catheter) with selected preparation and apply lubricant to tip. Insert tip 1 ½ inches into the rectum. Allow mixture to enter into the rectum and retain in the rectum for as long as possible or at least 5 minutes (Ref).

Administration: Pediatric

Oral: Administer on an empty stomach 1 hour before meals and at bedtime; tablet may be broken or dissolved in water before ingestion; do not administer antacids within 30 minutes of administration; shake suspension well before use. In general, separate administration of other oral medications and sucralfate by at least 2 hours; consult drug interactions database for additional information.

Use: Labeled Indications

Duodenal ulcer: Short-term (≤8 weeks) treatment of active duodenal ulcers; maintenance therapy for duodenal ulcers (tablets only).

Use: Off-Label: Adult

Gastroesophageal reflux disease in pregnancy; Marginal (anastomotic) ulceration after bariatric surgery; Oral ulcers, simple recurrent stomatitis and ulcers associated with Behçet disease; Proctitis due to radiation; Upper GI toxicity following radiation therapy

Medication Safety Issues
Sound-alike/look-alike issues:

Sucralfate may be confused with salsalate

Carafate may be confused with Cafergot

Administration issues:

For oral or rectal administration only. Fatal pulmonary or cerebral embolism has been reported following inadvertent IV administration of sucralfate.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Antacids: May diminish the therapeutic effect of Sucralfate. Management: Consider separating the administration of antacids and sucralfate by at least 30 minutes. Risk D: Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Risk X: Avoid combination

Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Risk D: Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification

Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir. Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir. Risk D: Consider therapy modification

Cholic Acid: Sucralfate may decrease the absorption of Cholic Acid. Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of aluminum-containing products such as sucralfate to minimize the potential for a significant interaction. Risk D: Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Risk D: Consider therapy modification

Digoxin: Sucralfate may decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before sucralfate. Concomitant administration should be avoided. Monitor for decreased digoxin levels/effects with initiation of sucralfate therapy. Risk D: Consider therapy modification

Dolutegravir: Sucralfate may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after sucralfate. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after sucralfate. Risk D: Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Risk D: Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Risk D: Consider therapy modification

Furosemide: Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide. Management: Separate orally administered furosemide from sucralfate administration by at least 2 hours. Risk D: Consider therapy modification

Ketoconazole (Systemic): Sucralfate may decrease the serum concentration of Ketoconazole (Systemic). Risk C: Monitor therapy

Levoketoconazole: Sucralfate may decrease the absorption of Levoketoconazole. Risk X: Avoid combination

Levonadifloxacin: Sucralfate may decrease the serum concentration of Levonadifloxacin. Risk X: Avoid combination

Levothyroxine: Sucralfate may decrease the serum concentration of Levothyroxine. Risk C: Monitor therapy

Multivitamins/Fluoride (with ADE): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum may be increased. Sucralfate may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, sucralfate may impair the absorption of fluoride. Management: Avoid administration of aluminum-containing products, such as sucralfate, within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination altogether. Risk D: Consider therapy modification

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Risk D: Consider therapy modification

Phenytoin: Sucralfate may decrease the serum concentration of Phenytoin. Risk C: Monitor therapy

Phosphate Supplements: Sucralfate may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 2 hours before sucralfate may reduce the significance of the interaction. Risk D: Consider therapy modification

QuiNIDine: Sucralfate may decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine. Management: Administer quinidine at least 2 hours before sucralfate. Risk D: Consider therapy modification

Quinolones: Sucralfate may decrease the serum concentration of Quinolones. Management: Avoid concurrent administration of quinolones and sucralfate to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone. Risk D: Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Risk D: Consider therapy modification

Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat. Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products. Risk D: Consider therapy modification

Sulpiride: Sucralfate may decrease the serum concentration of Sulpiride. Management: Separate administration of sucralfate and sulpiride by at least 2 hours in order to minimize the impact of sucralfate on sulpiride absorption. Risk D: Consider therapy modification

Tetracyclines: Sucralfate may decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate. Risk D: Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation. Risk D: Consider therapy modification

Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products. Risk X: Avoid combination

Vitamin D Analogs: May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Management: Consider avoiding chronic use of aluminum and aluminum-containing products, such as sucralfate, in patients who are also taking active vitamin D analogs. If combined, monitor for signs and symptoms of aluminum-related toxicities. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Monitor for decreased vitamin K antagonist effects (eg, decreased INR, thrombosis) when these agents are combined and consider administering vitamin K antagonists at least 2 hours before sucralfate to minimize this interaction. Risk C: Monitor therapy

Pregnancy Considerations

Sucralfate is only minimally absorbed following oral administration. Based on available data, sucralfate does not appear to increase the risk of adverse fetal events when used during the first trimester. Sucralfate is considered acceptable for use in pregnancy (Dağlı 2017; Gomes 2018; Thélin 2020).

Breastfeeding Considerations

It is not known if sucralfate is present in breast milk.

Sucralfate is only minimally absorbed following oral administration. Although the manufacturer recommends that caution be exercised when administering sucralfate to breastfeeding women, use is considered acceptable (Dağlı 2017).

Dietary Considerations

Take with water on an empty stomach.

Monitoring Parameters

Blood glucose levels (in diabetic patients receiving oral suspension).

Mechanism of Action

Forms a complex by binding with positively charged proteins in exudates, forming a viscous paste-like, adhesive substance. This selectively forms a protective coating that acts locally to protect the gastric lining against peptic acid, pepsin, and bile salts.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Paste formation and ulcer adhesion: 1 to 2 hours; acid neutralizing capacity: ~14 to 16 mEq/1 g dose of sucralfate

Absorption: Minimal from GI tract

Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate

Metabolism: None

Excretion: Primarily urine (small amounts of sulfated disaccharide)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apo-sucralfate | Gastrofait | Ulsaheal;
  • (AR) Argentina: Antepsin | Gastromed | Netunal | Sucralfato denver farma | Sucralfort | Sucralmax | Vastacid;
  • (AT) Austria: Sucralan | Sucralbene | Sucralfat genericon | Sucralstad | Sucramed | Ulcogant;
  • (AU) Australia: Carafate | Ulcyte;
  • (BD) Bangladesh: Antepsin | Gastalfet | Gastonic | Gestalfet | Sucrol | Ucrafate | Ulfate | Ulsanic;
  • (BE) Belgium: Ulcogant;
  • (BF) Burkina Faso: Ulcar;
  • (BG) Bulgaria: Sucralfat | Venter;
  • (CH) Switzerland: Ulcogant;
  • (CI) Côte d'Ivoire: Sucrafil;
  • (CL) Chile: Gastrocol | Mulcatel | Sucralmax | Sulcran;
  • (CN) China: Di xian | Hua di | Shu ke fei | Sucrate | Wei xiao;
  • (CO) Colombia: Albisan | Alsucral | Antepsin | Dip | Sucralfato | Sugastrin | Treceptan;
  • (CZ) Czech Republic: Alsucral | Sucralan | Ulcogant | Venter;
  • (DE) Germany: Sucrabest | Sucralfat | Sucraphil | Ulcogant;
  • (DO) Dominican Republic: Etisucral | Eurogastro | Sucrassyl | Tenofed | Ulcogant;
  • (EC) Ecuador: Ciprid | Dip | Sucralgastric | Ulcon | Yastrep;
  • (EE) Estonia: Antepsin | Sucrabest | Venter;
  • (EG) Egypt: Gastrofait | Sucrofilmpan | Ulcar;
  • (ES) Spain: Tiblex | Urbal;
  • (FI) Finland: Alsucral | Antepsin | Succosa;
  • (FR) France: Keal | Sucralfate rpg | Sucralfate teva | Ulcar;
  • (GB) United Kingdom: Antepsin | Sucralfate kent;
  • (GR) Greece: Dolisec | Peptonorm;
  • (HK) Hong Kong: Apo-sucralfate | Sucari | Sucralfat Ratiopharm 1000 | Sucway | Ulsanic;
  • (HU) Hungary: Alusulin | Ulcogant | Venter;
  • (ID) Indonesia: Benofat | Dopepsa | Eficap | Episan | Kalpepsa | Lanpepsa | Lipepsa | Mucifat | Mucogard | Musin | Neciblok | Nucral | Pepco | Peptovell | Profat | Propepsa | Taxilan | Ulcron | Ulcumaag | Ulfat | Ulsafate | Ulsanic | Ulsicral | Ulsidex;
  • (IE) Ireland: Antepsin;
  • (IL) Israel: Ulsanic;
  • (IN) India: Acicrol | Ancool sf | Cral | Filcer | Gistress | Lenocarb s | Mac S | Macralfate | Mucobind | Pepsigard | Qpfate | Rab sf | Sft | Sigral | Skf | Sparacid | Stalfate | Sucfate | Sucrace | Sucracid | Sucraday | Sucrafil | Sucragel | Sucral | Sucralcoat | Sucramal | Sucramax | Sucramed | Sucrazen | Sufate | Sufrate | Suwin;
  • (IT) Italy: Antepsin | Crafilm | Sucrager | Sucralfato | Sucralfin | Sucramal | Sucrate | Sucroril | Sugast;
  • (JO) Jordan: Gastrofait;
  • (JP) Japan: Altsamin taiyo | Alusajust yoshindo | Ulcerlmin;
  • (KR) Korea, Republic of: Sucramed | Ulcermin;
  • (KW) Kuwait: Gastrofait;
  • (LB) Lebanon: Ulcar;
  • (LT) Lithuania: Alsucral | Gastrofait | Ulcogant | Venter;
  • (LU) Luxembourg: Keal | Sucrabest | Ulcogant;
  • (LV) Latvia: Alsucral | Antepsin | Peptonorm | Sucrabest | Sucralfat | Sucralfat genericon | Ulcogant | Venter;
  • (MA) Morocco: Keal | Sugast | Ulcar;
  • (MX) Mexico: Alivoato | Alomoon | Apo-lato | Discral | Duodenel | Grismar | Metixane | Mogamigue | Rextrem | Sucralfato | Ulsicral | Unival;
  • (MY) Malaysia: Alsucral | Apo-sucralfate | Ulcertec | Ulsanic;
  • (NG) Nigeria: Sucragel;
  • (NL) Netherlands: Sucralfaat | Sucralfaat gf | Sucralfaat Ratiopharm | Ulcogant;
  • (NO) Norway: Antepsin | Sucralan;
  • (NZ) New Zealand: Carafate;
  • (PE) Peru: Didunal | Kalfrex | Sucragant | Sucralex | Sucralflam | Sucralit | Sucralmax | Sucrate | Sucraxol | Sufacrato | Sulcran | Ulcoflux | Ulcogant;
  • (PH) Philippines: Iselpin | Sucragen;
  • (PK) Pakistan: Cidifen | Crafilm | Cralfate | Cralsim | Fynkofate | Grasfate | Lacrate | Medgel | Orafate | Radifate | Ralfate | Sate | Sofet | Sucfate | Sucmed | Sucradale | Sucrafate | Sucralmed | Sucrasel | Surate | Surlka | Ulcafate | Ulcerate | Ulcercure | Ulcoat | Ulcocid | Ulcode | Ulfate | Ulsanic;
  • (PL) Poland: Ancrusal | Ulcogant | Ulgastran | Venter;
  • (PR) Puerto Rico: Carafate;
  • (PT) Portugal: Calfate | Cinebil | Sucralfato | Sucralum | Ulcermin;
  • (PY) Paraguay: Acipront | Kotric | Sucral | Sulfitriec;
  • (RO) Romania: Gastrofait | Venter;
  • (RU) Russian Federation: Venter;
  • (SA) Saudi Arabia: Apo-sucralfate | Gastrofait | Ulsaheal;
  • (SE) Sweden: Andapsin;
  • (SG) Singapore: Alsucral | Ulcertec;
  • (SK) Slovakia: Ulcogant | Venter;
  • (TH) Thailand: Scf | Sucrafen | Sucral | Sucratab | Ulcefate | Ulcrafate | Ulsanic;
  • (TN) Tunisia: Ulcar | Ulcefix;
  • (TR) Turkey: Antepsin | Karfat;
  • (TW) Taiwan: Anwenin | Aso | Bigast | Salet | Scrat | Sucafate | Sucra | Sucral | Sucrate | Sucway | Suicrate | Suwel | Ulcegban | Ulcerban | Ulcerfate | Ulsanic | Ulsate | Weizip;
  • (UA) Ukraine: Alsucral | Aluzulin | Sucralfat kmp | Venter | Ventor;
  • (UY) Uruguay: Alusac | Cralfate | Historal | Sucralfato | Unaltec;
  • (VE) Venezuela, Bolivarian Republic of: Digifal | Dip | Exinol | Sucralfato | Ulciram | Ulcon | Ulcraf;
  • (VN) Viet Nam: Sarufone;
  • (ZA) South Africa: Ulcefate | Ulcetic | Ulsanic
  1. Abtahi-Naeini B, Saffaei A, Sabzghabaee AM, et al. Topical sucralfate for treatment of mucocutaneous conditions: a systematic review on clinical evidences. Dermatol Ther. 2022;35(4):e15334. doi:10.1111/dth.15334 [PubMed 35080090]
  2. Algozzine GJ, Hill G, Scoggins WG, et al. Sucralfate Bezoar. N Engl J Med. 1983;309(22):1387.
  3. Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999;135(5):529-532. doi:10.1001/archderm.135.5.529 [PubMed 10328192]
  4. Apo-Sucralfate (sucralfate) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; October 2018.
  5. Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med. 1989;86(6A):73-76. [PubMed 2735338]
  6. Barola S, Fayad L, Hill C, et al. Endoscopic management of recalcitrant marginal ulcers by covering the ulcer bed. Obes Surg. 2018;28(8):2252-2260. doi:10.1007/s11695-018-3162-7 [PubMed 29556889]
  7. Brice S, Lodi G . Recurrent aphthous stomatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 2, 2022.
  8. Carafate (sucralfate) suspension [prescribing information]. Madison, NJ: Allergan USA Inc; January 2023.
  9. Carafate (sucralfate) tablets [prescribing information]. Madison, NJ: Allergan USA, Inc; June 2018.
  10. Collard HR, Saint S, and Matthay MA, “Prevention of Ventilator-Associated Pneumonia: An Evidence-Based Systematic Review,” Ann Intern Med, 2003, 138(6):494-501. [PubMed 12639084]
  11. Cook D, Guyatt G, Marshall J, et al, “A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. Canadian Critical Care Trials Group,” N Engl J Med, 1998, 338(12):791-7. [PubMed 9504939]
  12. Czito BG, Meyer JJ, Willett CG. Overview of gastrointestinal toxicity of radiation therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 2, 2022.
  13. Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation. Turk J Gastroenterol. 2017;28(Suppl 1):S53-S56. [PubMed 29199169]
  14. Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis. 2006;2(4):455-459. doi:10.1016/j.soard.2006.03.004 [PubMed 16925380]
  15. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  16. Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know?. Ann Gastroenterol. 2018;31(4):385‐394. doi:10.20524/aog.2018.0264 [PubMed 29991883]
  17. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy. 2008;40(5):359-369. doi:10.1055/s-2007-995567 [PubMed 18494131]
  18. Gul YA, Prasannan S, Jabar FM, Shaker AR, Moissinac K. Pharmacotherapy for chronic hemorrhagic radiation proctitis. World J Surg. 2002;26(12):1499-1502. doi:10.1007/s00268-002-6529-8 [PubMed 12297939]
  19. Hemstreet BA. Use of sucralfate in renal failure. Ann Pharmacother. 2001;35(3):360-364. doi:10.1345/aph.10117 [PubMed 11261535]
  20. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538 [PubMed 34807007]
  21. Kliegman RM, Stanton BMD, St. Geme J, et al, eds. Nelson' s Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.
  22. Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci. 1991;36(1):103-107. doi:10.1007/BF01300096 [PubMed 1670631]
  23. Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci. 1999;44(5):973-978. doi:10.1023/a:1026612731210 [PubMed 10235606]
  24. Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III Controlled Evaluation of Sucralfate to Alleviate Stomatitis in Patients Receiving Fluorouracil-Based Chemotherapy. J Clin Oncol. 1997;15(3):1235-1238. [PubMed 9060567]
  25. Melko GP, Turco TF, Phelan TF, Sauers NM. Treatment of radiation-induced proctitis with sucralfate enemas. Ann Pharmacother. 1999;33(12):1274-1276. doi:10.1345/aph.19065 [PubMed 10630828]
  26. Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.
  27. O'Neill T; University of Michigan Health - Michigan Medicine. Carafate (sucralfate) enemas. https://www.med.umich.edu/1libr/MBCP/CarafateEnemas.pdf. Accessed June 1, 2022.
  28. Overdahl MC, Wewers MD. Acute Occlusion of a Mainstem Bronchus by a Rapidly Expanding Foreign Body. Chest. 1994;105(5):1600-1602. [PubMed 8181371]
  29. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol. 2006;101(7):1449-1457. doi:10.1111/j.1572-0241.2006.00635.x [PubMed 16863545]
  30. Phoa KN, Rosmolen WD, Weusten BLAM, et al; SURF investigators. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial). Gastrointest Endosc. 2017;86(1):120e2-129.e2. doi:10.1016/j.gie.2016.12.001 [PubMed 27956164]
  31. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209-1217. doi:10.1001/jama.2014.2511 [PubMed 24668102]
  32. Ranchet G, Gangemi O, Petrone M. Sucralfate in the treatment of pregnancy pyrosis. Il Sucralfato nel trattamento della pirosi gravidica. Giorn It Ost Gin. 1990;12(1):91-96.
  33. Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc. 2007;21(7):1090-1094. doi:10.1007/s00464-007-9285-x [PubMed 17514403]
  34. Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate suspension as a treatment of recurrent aphthous stomatitis. J Intern Med. 1994;236(3):341-343. doi:10.1111/j.1365-2796.1994.tb00805.x [PubMed 8077892]
  35. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749-757. doi:10.1111/j.1365-2036.2005.02654.x [PubMed 16225482]
  36. Robertson JA, Salusky IB, Goodman WG, et al. Sucralfate, Intestinal Aluminum Absorption, and Aluminum Toxicity in a Patient on Dialysis. Ann Intern Med. 1989;111(2):179-181. [PubMed 2742249]
  37. Royal United Hospitals Bath NHS Foundation Trust. Sucralfate enemas. https://www.ruh.nhs.uk/patients/services/gastroenterology/documents/GAS008_Sucralfate_Enema_Factsheet.pdf. Published February 2022. Accessed June 1, 2022.
  38. Sangro B, Martínez-Urbistondo D, Bester L, et al. Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review. Hepatology. 2017;66(3):969-982. doi:10.1002/hep.29207 [PubMed 28407278]
  39. Schulman AR, Thompson CC. Complications of bariatric surgery: what you can expect to see in your GI practice. Am J Gastroenterol. 2017;112(11):1640-1655. doi:10.1038/ajg.2017.241 [PubMed 28809386]
  40. Soylu Özler G, Okuyucu Ş, Akoğlu E. The efficacy of sucralfate and chlorhexidine as an oral rinse in patients with recurrent aphthous stomatitis. Adv Med. 2014;2014:986203. doi:10.1155/2014/986203 [PubMed 26556433]
  41. Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: results of an international survey. Obes Surg. 2014;24(5):741-746. doi:10.1007/s11695-013-1152-3 [PubMed 24347350]
  42. Sulcrate and Sulcrate Suspension Plus (sucralfate) [product monograph]. Mont-St-Hilaire, Quebec, Canada: Aptalis Pharma Canada Inc; September 2013.
  43. Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Ther. 2020;51(4):421‐434. doi:10.1111/apt.15611 [PubMed 31950535]
  44. van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60(6):765-773. doi:10.1136/gut.2010.229310 [PubMed 21209124]
Topic 9953 Version 403.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟